WENDY ROGERS: Open Payments
NPI 1437749264 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,364 in 249 payments from 14 companies in 2025. Trend: 2023 $2,310 · 2024 $2,696 · 2025 $4,364
Food & beverage: $4,292Education: $71
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 39 | $824 |
| Neurocrine BioSciences, Inc. | 32 | $699 |
| Vanda Pharmaceuticals Inc. | 31 | $645 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $504 |
| Teva Pharmaceuticals USA, Inc. | 36 | $464 |
| E.R. Squibb & Sons, L.L.C. | 22 | $416 |
| ABBVIE INC. | 32 | $372 |
| Alkermes, Inc. | 12 | $170 |
| Lundbeck LLC | 4 | $73 |
| Axsome Therapeutics, Inc. | 3 | $66 |
Products named: REXULTI, INGREZZA, FANAPT, CAPLYTA, COBENFY, VRAYLAR, AUSTEDO XR, UZEDY.
Industry payments across TX — which companies pay providers there.
